Viromed Medical AG (XTER:VME) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


XTER:VME Viromed Medical AG XTER:VME
15 GF Score
Price €7.20
! 5 Warning Signs
View Full Analysis

What is Viromed Medical AG Research & Development?

Viromed Medical AG XTER:VME -2.04% 15 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 15/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Viromed Medical AG's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Viromed Medical AG  (XTER:VME) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Viromed Medical AG Research & Development Related Terms

Viromed Medical AG Research & Development Historical Data

* Premium members only.

The historical data trend for Viromed Medical AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viromed Medical AG Research & Development Chart

Viromed Medical AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00 0.00 0.00

Viromed Medical AG Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTER:VME
15GF Score
Viromed Medical AG XTER:VME
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viromed Medical AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Viromed Medical AG (XTER:VME) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Viromed Medical AG and its competitors.
Is Viromed Medical AG's Research & Development too high?
Viromed Medical AG's current Research & Development is €0.00 Mil. Overall, Viromed Medical AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's Research & Development compare to ABT and SYK?
Viromed Medical AG's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Viromed Medical AG and its competitors. Viromed Medical AG's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current Research & Development of €0.00 Mil. The current Research & Development is €0.00 Mil. Viromed Medical AG's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viromed Medical AG Business Description

Address Hauptstrasse 105, Rellingen, Pinneberg, SH, DEU, 25462
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
15GF Score

Get the complete analysis for XTER:VME

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.20
Price